<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084950</url>
  </required_header>
  <id_info>
    <org_study_id>PRO_CSM_02_2021</org_study_id>
    <nct_id>NCT05084950</nct_id>
  </id_info>
  <brief_title>Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)</brief_title>
  <acronym>MonaVacc</acronym>
  <official_title>Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Scientifique de Monaco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health Affairs, Monaco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Scientifique de Monaco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe&#xD;
      Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of&#xD;
      time due to the rapid spread of the virus. These vaccines use different and sometimes&#xD;
      innovative technologies, such as the use of ribonucleic acid (RNA), or a non-replicating&#xD;
      viral vector. Efficacy ranging from 70-90% in the first weeks after the second injection of&#xD;
      these vaccines has been reported, with side effects whose causality remains to be determined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Covid-19 Neutralizing Antibodies Measurment</measure>
    <time_frame>24-month period</time_frame>
    <description>Inform any individual who has been infected with or vaccinated against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have about their level of immune protection, through a bi-annual follow-up</description>
  </primary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>SARS-CoV-2</condition>
  <condition>COVID-19</condition>
  <condition>Vaccines</condition>
  <condition>Antibody</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This is a single-centre prospective observational study in the general population of the&#xD;
        Principality of Monaco, attending the community public health center of Monaco, for Covid&#xD;
        testing and/or vaccination.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must live in the Principality of Monaco&#xD;
&#xD;
          -  Deliver a written consent to participate to the study&#xD;
&#xD;
          -  And/Or Have been infected with SARS-CoV-2&#xD;
&#xD;
          -  And/Or Have been, or are about to be, vaccinated against SARS-CoV-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - None of the above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric VOIGLIO, MD, PhD</last_name>
    <phone>+37798984850</phone>
    <email>evoiglio@gouv.mc</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas ALTHAUS, MD, PhD</last_name>
    <phone>+37798984850</phone>
    <email>talthaus@gouv.mc</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre National de Depistage - Espace Leo Ferre</name>
      <address>
        <city>Monaco</city>
        <zip>98000</zip>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric VOIGLIO, MD, PhD</last_name>
      <phone>+37798984850</phone>
      <email>evoiglio@gouv.mc</email>
    </contact>
    <contact_backup>
      <last_name>Thomas ALTHAUS, MD, PhD</last_name>
      <email>talthaus@gouv.mc</email>
    </contact_backup>
    <investigator>
      <last_name>Eric VOIGLIO, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas ALTHAUS, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Herve RAPS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier DEJOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick RAMPAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Monaco</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

